nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2
|
Foster, Scott A. |
|
2016 |
29 |
4 |
p. 477-493 17 p. |
artikel |
2 |
A SIRT2-Selective Inhibitor Promotes c-Myc Oncoprotein Degradation and Exhibits Broad Anticancer Activity
|
Jing, Hui |
|
2016 |
29 |
4 |
p. 607- 1 p. |
artikel |
3 |
Blood-Brain Barrier Breakdown Determines Differential Therapeutic Outcome in Genetically Diverse Forms of Medulloblastoma
|
Guerit, Sylvaine |
|
2016 |
29 |
4 |
p. 427-429 3 p. |
artikel |
4 |
Defining and Targeting the Oncogenic Drivers of Neuroendocrine Prostate Cancer
|
Carver, Brett S. |
|
2016 |
29 |
4 |
p. 431-432 2 p. |
artikel |
5 |
Deletion Mutations Keep Kinase Inhibitors in the Loop
|
Freed, Daniel M. |
|
2016 |
29 |
4 |
p. 423-425 3 p. |
artikel |
6 |
Exploiting the Epigenome to Control Cancer-Promoting Gene-Expression Programs
|
Brien, Gerard L. |
|
2016 |
29 |
4 |
p. 464-476 13 p. |
artikel |
7 |
Genetic and Epigenetic Silencing of MicroRNA-203 Enhances ABL1 and BCR-ABL1 Oncogene Expression
|
Bueno, María J. |
|
2016 |
29 |
4 |
p. 607-608 2 p. |
artikel |
8 |
Glycoholics Anonymous: Cancer Sobers Up with mTORC1
|
Fu, Vivian |
|
2016 |
29 |
4 |
p. 432-434 3 p. |
artikel |
9 |
Interfering with CCL5/CCR5 at the Tumor-Stroma Interface
|
Bronte, Vincenzo |
|
2016 |
29 |
4 |
p. 437-439 3 p. |
artikel |
10 |
Intratumoral Heterogeneity of the Epigenome
|
Mazor, Tali |
|
2016 |
29 |
4 |
p. 440-451 12 p. |
artikel |
11 |
Kicking Genomic Profiling to the Curb: How Re-wiring the Phosphoproteome Can Explain Treatment Resistance in Glioma
|
Lam, Fred C. |
|
2016 |
29 |
4 |
p. 435-436 2 p. |
artikel |
12 |
Killing Lymphoma with Smac-Mimetics: As Easy as ABC?
|
Nachbur, Ueli |
|
2016 |
29 |
4 |
p. 425-427 3 p. |
artikel |
13 |
Long Noncoding RNAs in Cancer Pathways
|
Schmitt, Adam M. |
|
2016 |
29 |
4 |
p. 452-463 12 p. |
artikel |
14 |
Medulloblastoma Genotype Dictates Blood Brain Barrier Phenotype
|
Phoenix, Timothy N. |
|
2016 |
29 |
4 |
p. 508-522 15 p. |
artikel |
15 |
miR-126 Regulates Distinct Self-Renewal Outcomes in Normal and Malignant Hematopoietic Stem Cells
|
Lechman, Eric R. |
|
2016 |
29 |
4 |
p. 602-606 5 p. |
artikel |
16 |
mTORC1-Dependent Metabolic Reprogramming Underlies Escape from Glycolysis Addiction in Cancer Cells
|
Pusapati, Raju V. |
|
2016 |
29 |
4 |
p. 548-562 15 p. |
artikel |
17 |
N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells
|
Lee, John K. |
|
2016 |
29 |
4 |
p. 536-547 12 p. |
artikel |
18 |
Single-Cell Phosphoproteomics Resolves Adaptive Signaling Dynamics and Informs Targeted Combination Therapy in Glioblastoma
|
Wei, Wei |
|
2016 |
29 |
4 |
p. 563-573 11 p. |
artikel |
19 |
SnapShot: Renal Cell Carcinoma
|
Ricketts, Christopher J. |
|
2016 |
29 |
4 |
p. 610-610.e1 5491 p. |
artikel |
20 |
Spontaneous Hepatocellular Carcinoma after the Combined Deletion of Akt Isoforms
|
Wang, Qi |
|
2016 |
29 |
4 |
p. 523-535 13 p. |
artikel |
21 |
Targeting Non-proteolytic Protein Ubiquitination for the Treatment of Diffuse Large B Cell Lymphoma
|
Yang, Yibin |
|
2016 |
29 |
4 |
p. 494-507 14 p. |
artikel |
22 |
Targeting PI3K Signaling in Cancer: A Cautionary Tale of Two AKTs
|
Fortin, Jérôme |
|
2016 |
29 |
4 |
p. 429-431 3 p. |
artikel |
23 |
The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice
|
Townsend, Elizabeth C. |
|
2016 |
29 |
4 |
p. 574-586 13 p. |
artikel |
24 |
Tumoral Immune Cell Exploitation in Colorectal Cancer Metastases Can Be Targeted Effectively by Anti-CCR5 Therapy in Cancer Patients
|
Halama, Niels |
|
2016 |
29 |
4 |
p. 587-601 15 p. |
artikel |